Meloxicam/Kleva 15 Mg / 1,5 Ml

Meloxicam, the active ingredient in Meloxicam/Kleva 15 Mg / 1,5 Ml, is a nonsteroidal anti-inflammatory drug (NSAID) presented as a 15 mg/1.5 mL injectable solution for intramuscular use. It treats pain and inflammation associated with osteoarthritis, rheumatoid arthritis, and postoperative conditions in adult patients.

GNH USA supplies Meloxicam/Kleva 15 Mg / 1,5 Ml as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Meloxicam is an NSAID that reduces inflammation by targeting the cyclooxygenase‑2 pathway.

- Osteoarthritis: reduces joint pain and swelling. - Rheumatoid arthritis: alleviates chronic inflammatory pain. - Post‑operative pain: provides analgesia after surgical procedures. - Acute musculoskeletal pain: offers rapid relief of pain and inflammation.

Adverse reactions may occur with meloxicam use.

Common Side Effects: - Nausea: mild stomach upset. - Headache: transient discomfort. - Injection site pain: local discomfort at the intramuscular site. - Diarrhea: loose stools.

Serious or Rare Side Effects: - Gastrointestinal ulcer or bleeding. - Severe skin reactions such as Stevens‑Johnson syndrome. - Renal impairment: reduced kidney function.

Meloxicam requires careful patient assessment before and during therapy.

- Renal function: assess baseline kidney function and monitor periodically. - Hepatic status: avoid use in patients with severe liver disease. - Cardiovascular risk: use cautiously in patients with known heart disease or thrombotic history. - Hypersensitivity: contraindicated in individuals with known allergy to NSAIDs or meloxicam. - Pregnancy and lactation: safety not established; use only if benefits outweigh risks. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Meloxicam can interact with several drug classes, requiring vigilance.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin): heightened bleeding risk. - Lithium: elevated serum lithium concentrations. - Methotrexate: increased toxicity risk.

Moderate Interactions (Monitor Closely): - ACE inhibitors or ARBs: possible reduction in renal function. - SSRIs or SNRIs: additive risk of gastrointestinal bleeding.